Laws, regulations, and policies concerning reimbursement are complex and are updated frequently. Liquid biopsy can be used as an alternative to tissue testing14,15 Liquid biopsy may identify actionable mutations like KRAS G12C when tissue quantity is not sufficient14 NCCN Guidelines state that ...
2. Nadal E. et al. KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma. J Thorac Oncol. 2014; 9: 1513-1522. 3. Jones R.P. et al. Specific mutations in KRAS codon 12 ...
9. Ella A Eklund, Clotilde Wiel, Henrik Fagman, et al. KRAS Mutations Impact Clinical Outcome in Metastatic Non-Small Cell Lung Cancer.[J] .Cancers (Basel), 2022, 14: 0. 10. 中国临床肿瘤学会(CSCO)非小细胞...
This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should ...
However, with up to 40% of CRC cases harboring KRAS mutations, therapeutic targeting of RAS has been an area of great need. The development of KRASG12C inhibitors has led to the FDA approval of drugs for treating non鈥搒mall cell lung cancer. Recently, these and other newly developed ...
Exon 2 mutations have been associated with reduced response rates or resistance to EGFR inhibitors in non-small cell lung and colorectal cancer. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of...
2. Role of KRAS in normal cell homeostasis and disease 3. Epidemiology of KRAS-activating mutations: incidence and biology in advanced NSCLC 4. Advances in the treatment of KRAS-mutant NSCLC 5. Overlap between tumor mutational burden, PD-L1 expression, co-mutations, and KRAS G12C-mutant NSCLC...
29. TheKRASG12Dmutation has an intrinsic wildtype and SOS1 guanine exchange activities while theKRASQ61mutation has deficiencies in GTP hydrolysis27,30. TheKRASG12Rmutation, which accounts for approximately 15% of theKRASmutations in pancreatic cancer but less than 1% of theKRASmutations in lung...
However, testing is currently often confined to clinical trials or academic institutions, and biomarker testing algorithms vary according to country and regional guidelines (reviewed in Kerr et al. [62]). In terms of liquid biopsy testing, non-tumor derived mutations that expand during clonal ...
GFH-375: 一种KRAS G12D抑制剂药物,由Verastem, Inc. (Verastem, Inc.)公司最早进行研发,目前全球最高研发状态为临床1/2期,作用机制: KRAS G12D抑制剂(KRAS G12D突变抑制剂),治疗领域: 肿瘤,消化系统疾病,内分泌与代谢疾病,在研适应症: 晚期恶性实体瘤,KRAS G12D突变实